GlassScriptPhysician profile
Kyle Fritz Ostrom
NPI 1376746743
$1,676.52
in general payments reported to CMS, 2019-2025
14 companies · $178 in 2025
The $178 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $294 · 2020: $50.08 · 2021: $196 · 2022: $271 · 2023: $380 · 2024: $307 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $788 · Education: $77.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $787.64 |
| Education | $77.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $639.90 | 2021-2024 | |
| Novo Nordisk INC | $297.58 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $144.24 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $106.53 | 2023 | Xarelto |
| Merck Sharp & Dohme LLC | $85.39 | 2019 | |
| Lundbeck LLC | $77.08 | 2025 | Rexulti |
| Lilly USA, LLC | $69.49 | 2022-2023 | Mounjaro, Trulicity |
| Glaxosmithkline, LLC. | $57.19 | 2019-2025 | Arexvy, Trelegy Ellipta, Bexsero |
| Amgen INC. | $54.06 | 2019-2024 | Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $53.94 | 2022-2025 | Airsupra |
| Sanofi-Aventis U.S. LLC | $31.56 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.68 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.17 | 2021 | |
| Novartis Pharmaceuticals Corporation | $16.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Ostrom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.